SBT-200

SBT-200 is a preclinical-stage therapeutic candidate developed by Singh Biotechnology. It is designed as an intraocular treatment targeting KRAS and STAT3 for neovascular diseases of the eye, including acute macular degeneration, diabetic retinopathy, and other neovascular ocular conditions. The drug's mechanism involves inhibition of both KRAS and signal transducer and activator of transcription 3 pathways, which are implicated in pathological angiogenesis and inflammation in retinal diseases. The modality has not been explicitly stated but is likely to be a biologic or antibody-based therapy given the developer’s pipeline focus[1].